Möchten Sie immer auf dem neuesten Stand bleiben?

Neura Health Secures $11.4M Series A led by American Heart Association's Go Red for Women Venture Fund to expand tech-enabled neurology care model.

Angelini Pharma ottiene un'opzione esclusiva per acquisire i diritti globali di sviluppo e commercializzazione al di fuori della Repubblica di Corea, della Cina, di Hong Kong, di Macao e Taiwan di...

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Ass

Dublin, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The "Europe Refractory Epilepsy Treatment Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.The Europe...

Dublin, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Refractory Epilepsy Treatment Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.The...

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025Phase 2 trial of RAP-219 in bipolar mania has been...

CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)